A landmark regulatory double for GSK Dominates health sector newsflow today, as its once-monthly liver therapy secures simultaneous fast-track recognition on both sides of the Atlantic. Elsewhere, clinical data out of the ICU and a high-profile board appointment round out a substantive morning for healthcare investors.
GSK's efimosfermin earns dual fast-track status
GSK (LSE:GSK), trading at 2021.0p (+0.05%), has secured FDA Breakthrough Therapy designation And EMA PRIME status For efimosfermin, its investigational once-monthly therapy targeting metabolic dysfunction-associated steatohepatitis. The designations follow Phase II data demonstrating improved liver fibrosis and MASH resolution in patients with F2/F3 disease, the moderate-to-advanced fibrosis stages where therapeutic options remain Both designations are designed to accelerate development and regulatory dialogue for treatments addressing serious unmet need.
Delaware court clips TESARO's anticipatory breach claim
On the legal front, GSK's subsidiary TESARO has had its anticipatory breach claim dismissed by the Delaware Chancery Court following a motion brought by AnaptysBio. The court left TESARO's declaratory judgment claim intact, meaning the dispute is not fully resolved, but the ruling removes one avenue of recovery for the GSK unit. The outcome adds a layer of legal complexity to GSK's portfolio management without materially shifting the group's near-term commercial outlook.
Seaport Therapeutics adds Intra-Cellular founder to board
PureTech Health (LSE:PRTC), up 125.2p (+2.12%), sees its founded entity Seaport Therapeutics strengthen its leadership with the appointment of Dr Sharon Mates To its board. Mates founded Intra-Cellular Therapies and served as its CEO, overseeing the development and commercialisation of treatments in neuropsychiatry, the precise domain Seaport is targeting. The addition brings direct late-stage development and commercial launch experience to a company still building its pipeline credentials.
Ondine ICU data shows 39.5% pneumonia reduction
Ondine Biomedical (LSE:OBI) Advances 13.0p (+4.0%) After its pilot ICU study delivered a 39.5% reduction in pneumonia Among patients treated with its nasal photodisinfection technology. The results have been accepted for oral and poster presentation at the Canadian Critical Care Nursing Conference In September, a platform that extends the clinical visibility of the data beyond the published study. ICU-acquired pneumonia carries significant mortality and cost burdens, and the scale of reduction reported positions Ondine's technology as a credible candidate for broader clinical evaluation.
AstraZeneca wins FDA nod for weekly Saphnelo autoinjector
AstraZeneca has secured FDA approval for the Saphnelo Pen, a once-weekly 120mg autoinjector For adults living with moderate to severe systemic lupus erythematosus. The approval is grounded in positive Phase III TULIP-SC Data and represents a meaningful shift in the Saphnelo delivery profile, moving from intravenous infusion to self-administration. The convenience upgrade has the potential to broaden the addressable patient population and reduce the clinical infrastructure burden associated with treatment.
